Pulsed Laser Light and Nano-encapsulated Ocular Dyes for Advanced Therapies in the Eye
DYE-LIGHT aims to enhance ocular drug delivery and safety by utilizing low-energy pulsed-lasers with nano-encapsulated dyes to facilitate targeted treatment of severe ocular diseases.
Projectdetails
Introduction
Ocular diseases affect the quality of life of millions of patients. Despite improvements in pharmacological treatments, the arsenal of medications to treat severe ocular diseases today remains rather restricted to traditional drugs.
Need for Novel Administration Methods
The use of most modern biotherapeutics like proteins and nucleic acids could be a major step forward. However, current ways of administration such as eye drops and intravitreal injections are no longer sufficient to deliver these drugs to most targets in the eye. Therefore, novel concepts allowing biotherapeutics to safely overcome ocular barriers are of high interest.
Safety Concerns in Ocular Surgery
In ocular surgery, pulsed-lasers (P-Ls) are used for ‘tissue cutting’, though safety concerns remain. DYE-LIGHT hypothesizes that strategies which would allow the use of P-Ls in the eye at much lower energy than today could considerably improve safety and pave the way for both novel ocular therapies and advanced surgical interventions.
Exploration of Vital Dyes
DYE-LIGHT will explore vital dyes, as used by ocular surgeons to stain tissues, as photosensitizers. DYE-LIGHT follows the recent observation that P-L irradiation of ocular dyes can result in the formation of water vapor nanobubbles (‘dye-based nanobubbles’) and thermophoretic transport (‘dye-based thermophoresis’).
Energy Efficiency
Interestingly, these biophysical phenomena occur at a laser energy that is ~ 1000 times less than a P-L alone. As compared to free dyes, dyes encapsulated in nanocarriers are expected to penetrate less into the retina, which might improve safety.
Focus on Nano-Encapsulated Dyes
Therefore, the focus in DYE-LIGHT will be on nano-encapsulated ocular dyes. DYE-LIGHT will explore the potential of dye-based nanobubbles for:
- Delivery of nucleic acids in the corneal endothelium
- Spatial selective vitreolysis in the eye
Controlled Transport of Nanomedicines
Finally, DYE-LIGHT will explore dye-based thermophoresis for controlled transport of nanomedicines injected in the vitreous towards the retina. If successful, this might open new perspectives to improve the efficacy of retinal drug and gene delivery.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 1.499.351 |
Totale projectbegroting | € 1.499.351 |
Tijdlijn
Startdatum | 1-9-2023 |
Einddatum | 31-8-2028 |
Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- UNIVERSITEIT GENTpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Method for Integrated All-Optical Biological Analysis at ScaleDeveloping an all-optical platform for precise optogenetic probing and automated data analysis to enhance research in neuroscience, developmental biology, and cancer. | ERC Proof of... | € 150.000 | 2024 | Details |
Targeting epilepsy with phototherapeuticsThis project aims to develop targeted photoactivatable drugs to control focal epilepsy, minimizing side effects and potentially transforming treatment options for intractable cases. | ERC Starting... | € 1.499.375 | 2022 | Details |
Engineering of bacteria to see lightEOS aims to develop biohybrid living materials by inducing light sensitivity in motile bacteria for remote drug delivery, using a novel "optobacterial-stimulation" method. | ERC Starting... | € 1.500.000 | 2024 | Details |
Optical imaging platform for high-throughput longitudinal studies of the eye in disease modelsThe OPTIMEYEZ project aims to enhance a novel multi-contrast optical imaging platform for non-invasive retinal studies, facilitating drug development in neurological diseases while reducing animal use. | ERC Proof of... | € 150.000 | 2023 | Details |
Lensless label-free nanoscopyThis project aims to develop deep UV lensless holotomographic nanoscopy for high-resolution, large-field imaging of live cells to enhance understanding of extracellular vesicles as disease biomarkers. | ERC Starting... | € 1.500.000 | 2024 | Details |
Method for Integrated All-Optical Biological Analysis at Scale
Developing an all-optical platform for precise optogenetic probing and automated data analysis to enhance research in neuroscience, developmental biology, and cancer.
Targeting epilepsy with phototherapeutics
This project aims to develop targeted photoactivatable drugs to control focal epilepsy, minimizing side effects and potentially transforming treatment options for intractable cases.
Engineering of bacteria to see light
EOS aims to develop biohybrid living materials by inducing light sensitivity in motile bacteria for remote drug delivery, using a novel "optobacterial-stimulation" method.
Optical imaging platform for high-throughput longitudinal studies of the eye in disease models
The OPTIMEYEZ project aims to enhance a novel multi-contrast optical imaging platform for non-invasive retinal studies, facilitating drug development in neurological diseases while reducing animal use.
Lensless label-free nanoscopy
This project aims to develop deep UV lensless holotomographic nanoscopy for high-resolution, large-field imaging of live cells to enhance understanding of extracellular vesicles as disease biomarkers.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
LUMINESCENT IMPLANTS AS PORTS FOR LIGHT-BASED THERAPIESThe project aims to develop PhotoTheraPorts for localized light delivery to enhance anti-inflammatory and neuroinhibitory drug efficacy, improving treatment precision for neuropathic pain and epilepsy. | EIC Pathfinder | € 2.999.840 | 2024 | Details |
Direct Selective Laser Trabeculoplasty (DSLT): Accessible glaucoma care in secondsBELKIN Vision's Direct Selective Laser Trabeculoplasty (DSLT) aims to revolutionize glaucoma treatment with an automated, non-contact device that simplifies the procedure for widespread use. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Next Generation Glioma Treatments using Direct Light TherapyGlioLighT aims to revolutionize glioma treatment by developing Direct Light Therapy (DLT) for targeted ROS generation, enhancing efficacy and safety while eliminating the need for toxic photosensitisers. | EIC Pathfinder | € 2.219.087 | 2024 | Details |
NATURAL INTRAOCULAR PHOTOACTIVATION OF COMPOUNDS TO FIGHT RETINOPATHIESThis project aims to revolutionize retinopathy treatment by developing orally bioavailable drugs that target retinal tissue, reducing side effects and improving access to care. | EIC Pathfinder | € 2.988.434 | 2022 | Details |
MULTIMODE NONLINEAR FIBER BASED ENDOSCOPIC IMAGING AND TREATMENTMULTISCOPE aims to revolutionize optical diagnostics and therapy by developing a dual-function endoscopic device for real-time optical biopsy and cold atmospheric plasma treatment in gastrointestinal care. | EIC Pathfinder | € 2.863.733 | 2024 | Details |
LUMINESCENT IMPLANTS AS PORTS FOR LIGHT-BASED THERAPIES
The project aims to develop PhotoTheraPorts for localized light delivery to enhance anti-inflammatory and neuroinhibitory drug efficacy, improving treatment precision for neuropathic pain and epilepsy.
Direct Selective Laser Trabeculoplasty (DSLT): Accessible glaucoma care in seconds
BELKIN Vision's Direct Selective Laser Trabeculoplasty (DSLT) aims to revolutionize glaucoma treatment with an automated, non-contact device that simplifies the procedure for widespread use.
Next Generation Glioma Treatments using Direct Light Therapy
GlioLighT aims to revolutionize glioma treatment by developing Direct Light Therapy (DLT) for targeted ROS generation, enhancing efficacy and safety while eliminating the need for toxic photosensitisers.
NATURAL INTRAOCULAR PHOTOACTIVATION OF COMPOUNDS TO FIGHT RETINOPATHIES
This project aims to revolutionize retinopathy treatment by developing orally bioavailable drugs that target retinal tissue, reducing side effects and improving access to care.
MULTIMODE NONLINEAR FIBER BASED ENDOSCOPIC IMAGING AND TREATMENT
MULTISCOPE aims to revolutionize optical diagnostics and therapy by developing a dual-function endoscopic device for real-time optical biopsy and cold atmospheric plasma treatment in gastrointestinal care.